Rachel Ann Connor

Now open to ages 2-17! The ELSA study is screening children and young adults across the UK for #T1D. Watch @parthnarendran explain what we've learned so far and why early detection matters. @BT1DUK @DiabetesUK @RenukaDias Learn more: elsadiabetes.nhs.uk

We are recruiting people with #type1diabetes for a new clinical study at the Royal Free Hospital London. Feel free to reach out using contact details on poster below to learn more ⬇️ #Type1DiabetesGrandChallenge #BreakthroughT1D #DiabetesUK @RoyalFreeChty @BT1DUK @DUK_research

We're pleased to see that the government recognises access to innovative medicines is essential to improving outcomes for patients. The proposed changes to the NICE cost effectiveness thresholds and methodology around quality of life assessment should make it easier for new treatments to reach people with T1D quicker. We are at a turning point for T1D treatments, with new ways of treating and curing T1D on the horizon. With this announcement, a potential barrier to these treatments has been lifted. Advanced therapies are expensive, so we welcome this deal. We look forward seeing more detail, and to working with government, the NHS, industry and those with T1D to ensure these changes mean improvements in treatments across the UK.

Exciting volunteering opportunity for a diabetes specialist nurse or a non-research active consultant to join our Scientific Advisory Council! You could provide insightful information, independent advice and critical opinion, guiding our research decisions, policies, and position statements. Find out more and apply: bit.ly/48QS8La Application deadline: Wednesday 29 October 2025.

In questions Dr Waibel considers the possibility of replicating the way this class of drug is used in other conditions: continue treatment until there is evidence that it is no longer having a beneficial effect. #EASD2025

As we saw from the first cut of the data Baracitinib ( a daily tablet) is effective at preserving C-peptide: this year two data shows that once treatment stops the effect stops. Possibly slightly bigger effect in adults? #EASD2025

I am back to Vienna hall for the Bandit trial 2 year outcomes presented by Dr Michaela Waibel. BANDIT uses a JAK inhibitor called baricitinib that is already used in other autoimmune conditions as an immune modulatory therapy in new onset (stage 3) #t1D #easd2025

Sanjoy Dutta closes the session reflecting on just how many immune modulatory agents are now being studied in ppl with T1D. He reminds everyone in the hall and watching online that now is the time to get ready for disease modifying therapies in T1D in clinical practice #EASD2025

In the results ver-a-T1D wasn’t shown to have a statistically significant impact over placebo, although there are trends toward benefit. The placebo group didn’t show as much C peptide decline as expected, which is interesting: more work needed to understand this #EASD2025

Up bright and early for the 7:15 session chaired by @BreakthroughT1D Chief Scientific Officer Sanjoy Durga and Prof Jay Skyler of Miami looking forward to MELD-ATG and VER-A-T1D trial results #EASD2025

A sobering line at the bottom of this slide, which shows the evidence from multiple clinical studies of how change can be made: most people with diabetes can’t access this level of support… but Prof Speight is trying to change that with an online learning tool #easd2025

Prof Speight introduces us to the Com-B (pronounced ‘combi’) model showing how the complex behaviours needed to prevent hypoglycaemia comes together. Note the importance of stigma as a factor affecting the opportunity people feel they have to manage hypos #easd2025

After a lot of meetings I’m in my last session of the day: recurrent severe hypoglycaemic events: what to do? chaired by Dr Eelco de Koning we will have three speakers presenting some answers to this question: first up Dr Hans Devries with ‘technology’ #EASD2025